Ontology highlight
ABSTRACT:
SUBMITTER: Oki Y
PROVIDER: S-EPMC5278952 | biostudies-literature | 2013 Dec
REPOSITORIES: biostudies-literature
Oki Yasuhiro Y Westin Jason R JR Vega Francisco F Chuang Hubert H Fowler Nathan N Neelapu Sattva S Hagemeister Fredrick B FB McLaughlin Peter P Kwak Larry W LW Romaguera Jorge E JE Fanale Michelle M Younes Anas A Rodriguez Maria Alma MA Orlowski Robert Z RZ Wang Michael M Ouzounian Souzanne T ST Samaniego Felipe F Fayad Luis L
British journal of haematology 20131001 5
We conducted a prospective randomized phase II study to evaluate two chemotherapy regimens: (i) rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (R-HCVAD) alternating with rituximab, high-dose methotrexate, and cytarabine (R-MA) and (ii) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in diffuse large B-cell lymphoma (DLBCL). This study randomized patients aged ≤60 years with DLBCL and an age-adjusted international progno ...[more]